Most frequent complaints reported(multiple complaints per patient are possible)

Adverse effect may be due to disease and/or other underlying condition and medication/treatment may not be causative factor

DRUG RATING DETAILS (RANK BASED ON RATINGS OF SIMILAR DRUGS; SEE TABLE AT BOTTOM)

Drug Brand Name	Belviq XR
Drug Substance/Generic Name	lorcaserin
Number of Patients Complaining	422,621
Serious Reactions to Substance	304,874
Non Serious Reactions to Substance	142,818
Substance Not Effective Complaints	27,901
At-Ray Ratio (NSR/SR); Safety indicator, higher is safer	0.47
PP Ratio (Patients Complaining/Not Effective), higher is more effective	15.15
Drug Rating = PP Ratio* At-Ray Ratio	6.71

Summary (from Wikipedia)

Lorcaserin, currently marketed under the trade name Belviq and previously Lorqess during development, is a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating a type of serotonin receptor known as the 5-HT2C receptor in a region of the brain called the hypothalamus, which is known to control appetite.

Indications and Usage (from FDA label)

1 INDICATIONS AND USAGE BELVIQ/BELVIQ XR is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes) [see Dosage and Administration ( 2 )] Limitations of Use: The safety and efficacy of coadministration of BELVIQ/BELVIQ XR with other products intended for weight loss including prescription drugs (e.g., phentermine), over-the-counter drugs, and herbal preparations have not been established. The effect of BELVIQ/BELVIQ XR on cardiovascular morbidity and mortality has not been established. BELVIQ/BELVIQ XR is a serotonin 2C receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese) (1) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition, (e.g., hypertension, dyslipidemia, type 2 diabetes) (1) Limitations of Use: The safety and efficacy of coadministration with other products for weight loss have not been established (1) The effect of BELVIQ/BELVIQ XR on cardiovascular morbidity and mortality has not been established (1)

Copyright for images below belongs to manufacturer mentioned in label, presented for information only

Centrally acting antiobesity products

(17) Similar Drugs to Belviq XR ; Comparison Table Below
(Best drugs have high rating/ranking,high safety ratio and high effectivity ratio)

Brand Name (Click for details)	Active Ingredient	Drug ATC Class	Price Found (US $)	OVERALL Drug Rating